iSpecimen Inc.
ISPC Healthcare Diagnostics & Research
iSpecimen Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.9 million, down 79.2% from fiscal 2024. In the quarter to June 2026, revenue fell 78.7%, EPS grew 94.2% and free cash flow fell 257.7%, each against the same quarter a year earlier.
Follow ISPC
iSpecimen Inc. (ISPC) Piotroski F-score
iSpecimen Inc.'s Piotroski F-score for fiscal 2025 is 3 out of 9: 3 of nine tests of profitability, leverage and efficiency passed, unchanged from fiscal 2024.
Piotroski F-score, annual
Embed this chart
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|---|---|
| FY2025 | 3 | 0.00 |
| FY2024 | 3 | 0.00 |
| FY2023 | 3 | (1.00) |
| FY2022 | 4 | 2.00 |
| FY2021 | 2 | (5.00) |
| FY2020 | 7 | — |
How fiscal 2025’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | (111.09%) | (99.31%) | Fail | 0 |
| Positive operating cash flow | (4.24m) | (8.26m) | Fail | 0 |
| Rising return on assets | (111.09%) | (99.31%) | Fail | 0 |
| Cash flow above net income | 6.25m | 4.23m | Pass | 1 |
| Falling long-term leverage | 0.00 | 0.00 | Pass | 1 |
| Rising current ratio | 1.12 | 0.62 | Pass | 1 |
| No new shares issued | 115,100 | 17,800 | Fail | 0 |
| Rising gross margin | 1.25% | 42.93% | Fail | 0 |
| Rising asset turnover | 0.20 | 0.74 | Fail | 0 |
| Piotroski F-score | Weak — most fundamentals deteriorated | 3 | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| NDRA ENDRA Life Sciences Inc. compare | 6 |
| AWHL Aspira Women's Health Inc. compare | 5 |
| NOTVQ Inotiv, Inc. compare | 5 |
| PRPH ProPhase Labs, Inc. compare | 4 |
| ISPC iSpecimen Inc. | 3 |
| XWEL XWELL, Inc. compare | 3 |
| DMTKQ DermTech, Inc. compare | 3 |
| BIAF bioAffinity Technologies, Inc. compare | 2 |
| TTOO T2 Biosystems, Inc. compare | 2 |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover